Therapeutic agent for male sterility
The present invention is intended to provide an agent for treating male infertility which is highly effective to male infertility, and having few side effects. To achieve the object, an agent for treating male infertility comprising δ-amino levulinic acid shown by general formula (1), its derivative or salt thereof: R 2 R 1 NCH 2 COCH 2 CH 2 COR 3 (1) [wherein R 1 and R 2 independently represent a hydrogen atom, alkyl group, acyl group, alkoxycarbonyl group, aryl group, or aralkyl group; R 3 represents a hydroxy group, alkoxy group, acyloxy group, alkoxycarbonyloxy group, aryloxy group, aralkyloxy group or amino group] can be used.
1. A method of treating male infertility in a patient in need thereof comprising administering 6-amino levulinic acid shown by general formula (I), its derivative or salt thereof as an active ingredient,
R 2 R 1 NCH 2 COCH 2 CH 2 COR 3 (1)
wherein R 1 and R 2 independently represent a hydrogen atom, alkyl group, acyl group, alkoxycarbonyl group, aryl group, or aralkyl group; R 3 represents a hydroxy group, alkoxy group, acyloxygroup, alkoxycarbonyloxy group, aryloxy group, aralkyloxy group or amino group, to the patient in need thereof, wherein the male infertility is caused by oligozoospermia or asthenospermia.
2. The method of claim 1 , further comprising an iron compound as an active ingredient.
3. The method of claim 2 , wherein the iron compound is 1 or more compound(s) selected from ferric chloride, iron sesquioxide, sodium iron chlorophyllin, ferritin iron, ferrous citrate, iron sodium citrate, iron ammonium citrate, ferrous fumarate, ferrous pyrophosphate, ferric pyrophosphate, saccharated iron oxide, iron acetate, iron oxalate, ferrous succinate, iron sodium succinate citrate, heme iron, iron dextran, iron lactate, ferrous gluconate, iron sodium diethylenetriaminepentaacetate, iron ammonium diethylenetriaminepentaacetate, iron sodium ethylenediaminetetraacetate, iron ammonium ethylenediaminetetraacetate, iron triethylenetetraamine, iron sodium dicarboxymethylglutamate, and iron ammonium dicarboxymethylglutamate.
4. The method of claims 1 to 3 , wherein δ-amino levulinic acid, or salt thereof is administered in an amount of 0.001 mg to 10 g per 1 kg of body weight at one time.
5. The method of claim 2 or 3 , wherein the iron compound is administered in an amount of 0.001 mg to 10 g per 1 kg of body weight at one time.
6. The method of claims 1 to 3 , wherein the administration method is oral administration, intraperitoneal administration, intravenous administration, intramuscular administration, local administration to affected area, transdermal administration, or intrarectal administration.